Sanara MedTech Inc. (NASDAQ:SMTI) Given Consensus Rating of “Moderate Buy” by Brokerages

Shares of Sanara MedTech Inc. (NASDAQ:SMTI) have been given an average rating of “Moderate Buy” by the five research firms that are currently covering the stock, Marketbeat reports. One investment analyst has rated the stock with a sell recommendation, one has issued a hold recommendation, two have assigned a buy recommendation and one has issued a strong buy recommendation on the company. The average 12-month price objective among analysts that have issued ratings on the stock in the last year is $34.00.

Several brokerages recently commented on SMTI. Freedom Capital raised shares of Sanara MedTech to a “strong-buy” rating in a research note on Wednesday. Zacks Research raised shares of Sanara MedTech from a “strong sell” rating to a “hold” rating in a research note on Wednesday, June 10th. Weiss Ratings reissued a “sell (e+)” rating on shares of Sanara MedTech in a research note on Tuesday, April 21st. Wall Street Zen raised shares of Sanara MedTech from a “hold” rating to a “buy” rating in a research note on Saturday, May 16th. Finally, Lake Street Capital began coverage on shares of Sanara MedTech in a research note on Wednesday, April 15th. They issued a “buy” rating and a $32.00 price objective for the company.

Sanara MedTech Stock Performance

NASDAQ SMTI opened at $21.22 on Thursday. The company has a current ratio of 2.28, a quick ratio of 2.05 and a debt-to-equity ratio of 6.59. The firm has a market capitalization of $194.38 million, a price-to-earnings ratio of -5.63 and a beta of 1.21. The firm’s 50 day simple moving average is $20.62 and its 200 day simple moving average is $21.01. Sanara MedTech has a 1 year low of $16.05 and a 1 year high of $35.95.

Sanara MedTech (NASDAQ:SMTI) last posted its quarterly earnings results on Tuesday, March 24th. The company reported $0.04 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.11 by ($0.07). The firm had revenue of $27.55 million for the quarter, compared to analyst estimates of $27.90 million. Sanara MedTech had a negative return on equity of 3.19% and a negative net margin of 31.23%. As a group, research analysts expect that Sanara MedTech will post 0.16 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Sanara MedTech

Large investors have recently modified their holdings of the business. Lazard Asset Management LLC raised its stake in shares of Sanara MedTech by 63,100.0% during the second quarter. Lazard Asset Management LLC now owns 3,160 shares of the company’s stock valued at $89,000 after acquiring an additional 3,155 shares during the last quarter. Price T Rowe Associates Inc. MD raised its stake in shares of Sanara MedTech by 31.8% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 8,698 shares of the company’s stock valued at $204,000 after acquiring an additional 2,100 shares during the last quarter. Squarepoint Ops LLC raised its stake in shares of Sanara MedTech by 343.4% during the third quarter. Squarepoint Ops LLC now owns 31,383 shares of the company’s stock valued at $996,000 after acquiring an additional 24,305 shares during the last quarter. Marshall Wace LLP raised its stake in shares of Sanara MedTech by 144.3% during the second quarter. Marshall Wace LLP now owns 71,511 shares of the company’s stock valued at $2,030,000 after acquiring an additional 42,237 shares during the last quarter. Finally, Hsbc Holdings PLC bought a new position in shares of Sanara MedTech during the second quarter valued at $382,000. Institutional investors own 8.10% of the company’s stock.

Sanara MedTech Company Profile

Sanara MedTech is a medical technology company focused on developing and commercializing innovative devices for ear, nose and throat (ENT) healthcare. The company’s core offering centers on minimally invasive sinus dilation systems designed to treat chronic sinusitis and related conditions. These products leverage balloon catheter technology to expand sinus pathways and improve patient outcomes while reducing recovery times. In addition to sinus solutions, the portfolio extends to procedural tools and implants for otology and cranial applications.

With its legacy rooted in the assets of a former Johnson & Johnson business, Sanara MedTech combines decades of research and development in ENT therapies.